More transparency about the high pricing of cancer medicines can lower the costs


But only if you also make the R&D prices available

Research from NKI and UvA has shown that the costs of expensive cancer drugs can decrease significantly – without losing investments in Research & Development (R&D) – when governments and pharmaceutical companies provide full transparency about their negotiations and price breakdowns, including R&D costs.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.